Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: A single-center experience

Clinical Respiratory Journal

Volumn 6, Issue 1, 2012, Pages 56-64

  Briggs, Elissa Charlotte ^a   Nguyen, Thuan ^a   Wall, Michael Abraham ^a   Macdonald, Kelvin David ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antibiotics; Cystic fibrosis; Exacerbation; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIMICROBIAL THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTPATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RISK FACTOR; SOCIAL STATUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEDICAL AUDIT; MULTIVARIATE ANALYSIS; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84155164716     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00246.x     Document Type: Article

References (29)

1. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4): 360-7.
2. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1): 1-9.
3. Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV(1) decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4): 395-400.
4. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1): 64-72.
5. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335(3): 179-88.
6. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8): 918-51.
7. Kraynack NC, McBride JT. Improving care at cystic fibrosis centers through quality improvement. Semin Respir Crit Care Med. 2009;30(5): 547-58.
8. Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2007;(3): CD005405.
9. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet. 1987;1(8527): 235-7.
10. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, etal. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9): 802-8.
11. Sanders D, Bittner RCL, Rosenfield M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182: 627-32.
12. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001;163(6): 1331-7.
13. Scully BE, Neu HC, Parry MF, Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986;1(8485): 819-22.
14. Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC. Ciprofloxacin therapy in cystic fibrosis. Am J Med. 1987;82(4A): 196-201.
15. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J. 1997;16(6): 572-8.
16. Szaff M, Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand. 1982;71(5): 821-6.
17. Pressler T, Szaff M, Hoiby N. Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae infections in patients with cystic fibrosis. Acta Paediatr Scand. 1984;73(4): 541-7.
18. Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Arch Dis Child. 1990;65(3): 255-8.
19. Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, etal. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006;61(11): 969-74.
20. Sanders D, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010;45: 127-34.
21. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303(23): 2386-92.
22. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8): 814-21.
23. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3): 805-26.
24. Mekus F, Laabs U, Veeze H, Tummler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet. 2003;112(1): 1-11.
25. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, etal. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14): 1443-53.
26. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med. 2006;174(7): 780-6.
27. Jensen T, Pedersen SS, Hoiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol. 1987;6(6): 618-22.
28. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001;56(10): 746-50.
29. Peterson ML, Jacobs DR Jr, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics. 2003;112(3 Pt 1): 588-92.